DNA Genetics Announces Strategic Alliance Agreement With Vertically-Integrated Israeli Cannabis Company, UNIVO Pharmaceuticals


Ryan Allway

May 10th, 2021

News


LOS ANGELES, May 10, 2021 (GLOBE NEWSWIRE) — OG DNA Genetics (“DNA” or the “Company”), a globally recognized leading cannabis brand, today announced a licensing agreement (the “Agreement”) with UNIVO Pharmaceuticals LTD (“UNIVO”), an Israeli based medical cannabis company trading on the Tel Aviv stock exchange under the symbol UNVO.TA.

 

This Agreement will grant UNIVO license to the DNA brand and access to their proprietary library of award-winning genetics (including Kosher Kush) for use at the company’s 5-acre cultivation facility located in the south of Israel.

 

“We’re excited to announce our partnership with UNIVO Pharmaceuticals and our entry into the rapidly developing Israeli medical cannabis market. Through this partnership, we will be able to bring our unique varieties to Israel and develop new and exciting cannabis-derived medicinal products to export internationally. We couldn’t ask for a better partner to enter the Israeli medical cannabis market with than UNIVO Pharmaceuticals,” said Rezwan Khan, President of DNA Genetics.

 

“We are pleased to announce a strategic joint venture with DNA Genetics, a well-known global player in the field of cannabis, who has examined the Israeli market and partnered with us to build a joint international brand. We strongly believe that the technological and marketing capabilities of both companies will result in a high quality and competitive brand that will be launched shortly, which will contribute to our market presence both locally and outside our domestic Israeli market,” said Golan Bitton, CEO of UNIVO Pharmaceuticals.

 

“We are pleased to partner with DNA Genetics, one of the leading companies in the field of cannabis genetics and farming. Our professional teams will collaborate on Amit Farm to develop new cannabis strains while growing the best genetics and make available the best products using our leading global standard farming infrastructure for the benefit of patients in Israel and other countries,” said Omer Layani, Amit Farm Manager.

 

Since its inception, the genetics developed by DNA have won more than 200 awards, in all
categories, at the most prestigious cannabis events around the world – making DNA the global standard in breeding and growing truly best-in-class strains. These awards include the High Times’ Top 10 Strain of the Year, which was inducted into the High Times Seedbank Hall of Fame in 2009, the High Times’ 100 Most Influential People in the Industry, and the High Times’ Trail Blazers Award, for contributions made towards uniting the fields of entrepreneurship, politics, and medicine.

 

About OG DNA Genetics Inc.

DNA was rooted in Los Angeles and founded in Amsterdam in 2004 by Don Morris and Aaron Yarkoni. Over the last decade, the Company has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation. In a world that is increasingly opening up to commercial cannabis activity, DNA is positioned to become the first, truly geographically-diversified company with multiple partnerships with top-licensed producers and brands that have built their companies and global presence utilizing the “Powered by DNA” model. For more information, please visit www.dnagenetics.com.

 

Media Contact:
Kate Pasterkiewicz
Global Corporate Development Associate
DNA Genetics
kate@dnagenetics.com

 

About UNIVO Pharmaceuticals

UNIVO Pharmaceuticals is a vertically-integrated medical cannabis company covering all aspects of cultivation, manufacturing and distribution, and operate one of the largest, full technology growing areas, located in the south of Israel. Our highly experienced researchers hold PhDs in chemistry, analytical chemistry, biomedicine, and pharmaceuticals coming together to create innovative and dosage formed products for next-generation medical cannabis.

 

UNIVO possess initial licenses for the entire supply chain:

  • Growing, breeding and nursery
  • Production of medical cannabis products
  • Research and development
  • Distribution

 

Media Contact:
Sivan Caspi
Marketing and Sales Manager
UNIVO Pharmaceuticals
Sivan@univopharma.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading